189030-79-3

Upstream product

• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 189030-78-2 3-(R)-benzyloxycarbonyl-5-methylhexanoic acid 
• 100-51-6 benzyl alcohol 
• 189030-77-1 2R-isobutyl-succinic acid 1-benzyl ester 4-tert-butyl ester 
• 77509-00-3 phenylmethyl 4-methylpentanoate 
• 646-07-1 4-Methylpentanoic acid 

Downstream Products

• 189030-84-0 (R)-2-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-2-oxo-ethyl]-4-methyl-pentanoic acid ((S)-1-hydroxymethyl-2-phenyl-ethyl)-amide 
• 189030-86-2 (S)-2-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-2-oxo-ethyl]-4-methyl-pentanoic acid ((S)-1-hydroxymethyl-2-phenyl-ethyl)-amide 

Relevant academic research and scientific papers

Exploration of the importance of the P2-P3-NHCO-moiety in a potent di- or tripeptide inhibitor of calpain I: insights into the development of nonpeptidic inhibitors of calpain I.

Calpain I, an intracellular cysteine protease, has been implicated in the neurodegeneration following an episode of cerebral ischemia. In this paper, we report on a series of peptidomimetic ketomethylene and carbamethylene inhibitors of recombinant human calpain I (rh calpain I). Our study reveals that the -NHCO-moiety (possible hydrogen-bonding site) at the P2-P3 region of a potent tripeptide or a dipeptide inhibitor of calpain I is not a strict requirement for enzyme recognition. Compounds 7d ((R)-2-isobutyl-4-oxo-4-(9-xanthenyl)butanoic acid ((S)-1-formyl-3-methyl)butyl amide), 31 ((R)-2-isobutyl-4-(2-sulfonylnaphthyl)butyric acid ((S)1-formyl-3-methyl)butyl amide) and 34 ((R)-2-isobutyl-4-(2-sulfoxylnaphthyl)butyric acid ((S)-1-formyl-3-methyl)butyl amide) which exhibited good activity in the enzyme assay, also inhibited calpain I in a human cell line.